U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO Complete if Known 10/596,429 Application Number INFORMATION DISCLOSURE STATEMENT BY APPLICANT 12/17/2004 Filing Date Norihiro NISHIMOTO First Named Inventor Date Submitted: FEB 1 1 2011 1647 Art Unit (use as many sheets as necessary) **Examiner Name** Lorraine Spector 053466-0417 Sheet of Attorney Docket Number 1

	PADEMARKO				
Examin er Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		Number-Kind Code ² (if known)			Passages or Relevant Figures Appear
	G1	2005/0158317 A1	07/21/2005	Blay et al.	

FOREIGN PATENT DOCUMENTS						
Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴⁻ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т6	
G2	JP 08-311098 A	11/26/996	Daicel Chem. Ind. Ltd. et al.		Α	
G3	WO 03/048205 A2	06/12/2003	Universite Claude Bernard Lyon		Α _\	
	No. ¹	No. ¹ Country Code ³ Number ⁴ - Kind Code ⁵ (<i>if known</i>) G2 JP 08-311098 A	Cite No.1 Foreign Patent Document Country Code ³ Number MM-DD-YYYY Publication Date MM-DD-YYYY G2 JP 08-311098 A 11/26/996	Cite No.1 Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known) Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Documents G2 JP 08-311098 A 11/26/996 Daicel Chem. Ind. Ltd. et al. G3 WO 03/048205 A2 06/12/2003 Universite Claude Bernard	Cite No.1 Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known) Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Documents Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear G2 JP 08-311098 A 11/26/996 Daicel Chem. Ind. Ltd. et al. G3 WO 03/048205 A2 06/12/2003 Universite Claude Bernard	

		NON PATENT LITERATURE DOCUMENTS	•
Examiner Initials*	Cite No. ¹	TO I TOM (DOOK MAGAZING INTINAL CARIAL CUMPACIUM CATAINA ATA LATA DAGACE VALUMALIC	
	G4	Office Action dated January 13, 2011, in corresponding Mexican application No. PA/a/2006/005875, 2 pages.	
	G5	KATSUME et al., "Anti-Interleukin 6 (IL-6) Receptor Antibody Suppresses Castleman's Disease Like Symptoms Emerged in IL-6 Transgenic Mice," Cytokine, December 21, 2002, 20(6):304-311.	
-	G6	TSUNENARI et al., "Therapeutic Potential of Humanized Anti-interleukin-6 Receptor Antibody: Antitumor Activity in Xenograft Model of Multliple Myeloma," Anticancer Research, 1996, 16:2537-2544.	
	G7	NISHIMOTO et al., "Anti-interleukin 6 receotpr antibody treatment in rheumatic disease," Ann. Rheum. Dis., 2000, 59(Suppl 1):i21-i27.	
	G8	MIHARA et al., "IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F ₁ mice," Clin. Exp. Immunol., 1998, 112:397-402.	

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.